{"transactions":[{"id":910601,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-11T21:00:12.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":17730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":17730,"derivative":{"exercise_price":16.37,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":17730},"source":{"system":"sec-edgar","filing":"0001140361-26-004887","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000114036126004887/form4.xml","form_type":"4"}},{"id":910600,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-11T21:00:12.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":10690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 5,444 shares of common stock owned by the Reporting Person."}],"balance_after":21579,"source":{"system":"sec-edgar","filing":"0001140361-26-004887","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000114036126004887/form4.xml","form_type":"4"}},{"id":1184861,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-02T20:34:41.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2951,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") represented a contingent right to receive one Company Share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2951},"source":{"system":"sec-edgar","filing":"0000950170-25-049830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017025049830/ownership.xml","form_type":"4"}},{"id":1184860,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:34:41.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":67.77,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":4322},"source":{"system":"sec-edgar","filing":"0000950170-25-049830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017025049830/ownership.xml","form_type":"4"}},{"id":1184859,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:34:41.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":63.79,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":7009},"source":{"system":"sec-edgar","filing":"0000950170-25-049830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017025049830/ownership.xml","form_type":"4"}},{"id":1184858,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:34:41.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":55.48,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16757},"source":{"system":"sec-edgar","filing":"0000950170-25-049830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017025049830/ownership.xml","form_type":"4"}},{"id":1184857,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:34:41.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":60.03,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017025049830/ownership.xml","form_type":"4"}},{"id":1184856,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T20:34:41.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1567,"price":132,"value":206844.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-049830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017025049830/ownership.xml","form_type":"4"}},{"id":1254079,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-02-21T21:05:31.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":16279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":16279,"derivative":{"exercise_price":16.07,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":16279},"source":{"system":"sec-edgar","filing":"0001140361-25-005539","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000114036125005539/form4.xml","form_type":"4"}},{"id":1254078,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-21T21:05:31.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":10889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Comprised of, as of the transaction date, 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1)."}],"balance_after":10889,"source":{"system":"sec-edgar","filing":"0001140361-25-005539","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000114036125005539/form4.xml","form_type":"4"}},{"id":1319060,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-01-02T16:15:30.000Z","date":"2024-12-30","kind":"grant","planned":false,"acquired":true,"shares":20011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted to the reporting person on 12/30/2024 upon joining the ADMA Biologics, Inc. Board of Directors and will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":20011,"derivative":{"exercise_price":17.49,"expiration_date":"2034-12-30","underlying":"Common Stock","underlying_shares":20011},"source":{"system":"sec-edgar","filing":"0001140361-25-000079","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000114036125000079/form4.xml","form_type":"4"}},{"id":1469920,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T18:05:20.000Z","date":"2024-06-23","kind":"exercise","planned":false,"acquired":false,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0000950170-24-077470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017024077470/ownership.xml","form_type":"4"}},{"id":1469919,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T18:05:20.000Z","date":"2024-06-23","kind":"exercise","planned":false,"acquired":true,"shares":1567,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":1567,"source":{"system":"sec-edgar","filing":"0000950170-24-077470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017024077470/ownership.xml","form_type":"4"}},{"id":1476239,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T18:02:46.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":4322,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4322,"derivative":{"exercise_price":67.77,"exercise_date":"2025-06-14","expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":4322},"source":{"system":"sec-edgar","filing":"0000950170-24-075082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017024075082/ownership.xml","form_type":"4"}},{"id":1476238,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-18T18:02:46.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":2951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025)."}],"balance_after":2951,"derivative":{"underlying":"Common Stock","underlying_shares":2951},"source":{"system":"sec-edgar","filing":"0000950170-24-075082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000095017024075082/ownership.xml","form_type":"4"}},{"id":1843745,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-27T17:12:21.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7009,"derivative":{"exercise_price":63.79,"exercise_date":"2024-06-23","expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":7009},"source":{"system":"sec-edgar","filing":"0001209191-23-039929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000120919123039929/doc4.xml","form_type":"4"}},{"id":1843744,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-27T17:12:21.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024)."}],"balance_after":1567,"derivative":{"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0001209191-23-039929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000120919123039929/doc4.xml","form_type":"4"}},{"id":2234769,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T17:03:33.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":16757,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16757,"derivative":{"exercise_price":55.48,"exercise_date":"2023-06-09","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16757},"source":{"system":"sec-edgar","filing":"0001209191-22-036375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000120919122036375/doc4.xml","form_type":"4"}},{"id":2293039,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":66932,"kind":"person","name":"Salas Eduardo Rene","position":1,"cik":"0001924188","reported_name":"Salas Eduardo Rene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-21T16:54:37.000Z","date":"2022-04-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":60.03,"exercise_date":"2023-04-20","expiration_date":"2032-04-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-025186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1924188/000120919122025186/doc4.xml","form_type":"4"}}]}